Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Breast Neoplasms: HELP
Dr. Harold Burstein
Based on 101 articles published since 2007
||||
Expertise Level
The expertise of Dr. Harold Burstein ranks in the
  • Top 0.0012%
  • ... of 253,558 published authors worldwide on Breast Neoplasms
  • ... from 2007 through 2018
  • ... based on contributions to 101 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
World Expert badge
similar to this:
 
Aliases Burstein, H J   ·   Burstein, Harold J   ·   Burstein, H   ·   Burstein, Harold
Work Locations
Details
Most likely:    Harvard University   Contact    
2017
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts. · Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts2Associate Editor, JAMA. · Pubmed 27918782
  • Seth A. Wander, Erica L. Mayer, and Harold J. Burstein, Dana-Farber Cancer Institute; Brigham & Women's Hospital; Harvard Medical School, Boston, MA. · Pubmed 28580881
  • Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy. · Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. · Klinik St. Anna, Luzern, Switzerland. · German Breast Group, Neu-Isenburg, Germany. · Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Medical Oncology, Institut Jules Bordet, UniversitÕ Libre de Bruxelles, Brussels, Belgium. · Tumor and Breast Center ZeTuP, St. Gallen. · Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland. · Institut de Cancérologie Gustave Roussy, Villejuif, France. · Memorial Sloan Kettering Cancer Center, New York, USA. · Karolinska Institute and University Hospital, Stockholm, Sweden. · University of Bordeaux, Bordeaux, France. · Universitäts-Frauenklinik Tübingen, Tübingen, Germany. · Champalimaud Cancer Centre, Lisbon, Portugal. · Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. · Institut für Pathologie, Charité Universitätsmedizin Berlin, Berlin, Germany. · Azienda Usl Toscana Centro, Prato, Italy. · Rigshospitalet, Copenhagen, Denmark. · Peter McCallum Cancer Centre, Melbourne, Australia. · Marmara University School of Medicine, Istanbul, Turkey. · University of Toronto, Mount Sinai Hospital, Toronto, Canada. · University of Munich, München, Germany. · Comprehensive Cancer Center, University of Michigan, Ann-Arbor, USA. · National Taiwan University Hospital, Taipei, Taiwan. · University of Ulm, Ulm, Germany. · The National Cancer Institute, Cairo University, Cairo, Egypt. · Medical University of Gdansk, Gdansk, Poland. · Hospital Affiliated to Military Medical Science, Beijing, China. · Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrensky University Hospital, Gothenburg, Sweden. · Baylor College of Medicine, Houston, USA. · Institute of Oncology Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland. · Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Canada. · National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea. · Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. · LKH Salzburg, Paracelsus Medical University Clinics, Salzburg, Austria. · N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation. · Fudan University Cancer Hospital, Shanghai, China. · The Royal Marsden, Sutton, Surrey, UK. · Graduate School of Medicine Kyoto University, Sakyo-ku, Kyoto City, Japan. · Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. · University of Milan, Milan. · Istituto Europeo di Oncologia, Milan, Italy. · Hamamatsu Oncology Center, Hamamatsu, Japan. · McMaster University, Hamilton, Canada. · National Cancer Center, Chaoyang District, Beijing, China. · Pubmed 28838210
2016
  • Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI. · Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI · Pubmed 26931400
  • Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Department of Breast Oncology Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. Electronic address: · Department of Surgery, McGill Hospital, Boston, MA, USA. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Department of Clinical Medicine and Surgery, University Federico II, Corso Umberto I 40, Naples, Italy. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · General Surgery, Department of Advanced Biomedical Science, University Federico II, Corso Umberto I 40, Naples, Italy. Electronic address: · Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA. Electronic address: · Pubmed 27825710
  • Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. · Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA. · Program in Women's Oncology, Women and Infants Hospital of Rhode Island and Alpert Medical School of Brown University, Providence, RI, USA. · Department of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · Alliance Statistics and Data Center, M D Anderson Cancer Center, Houston, TX, USA. · Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. · Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA. · Department of Medical Oncology, City of Hope Medical Center, Los Angeles, CA, USA. · Department of Surgery, Mount Sinai School of Medicine, New York, NY, USA. · Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · Pubmed 27704226
  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. · Pubmed 27631400
  • Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. · Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. · Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA. · Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. · Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. · Pubmed 27484879
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison, New York. · Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. · Breast Cancer Research, Sarah Cannon Research Institute, Nashville, Tennessee. · Department of Medicine, Duke University Medical Center, Durham, North Carolina. · Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Chicago, Illinois. · Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco. · Department of Medicine, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis. · Department of Medicine, Washington University School of Medicine, St Louis, Missouri. · Department of Hematology Oncology, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, New York. · Department of Oncology, The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. · Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. · Department of Medicine, Massachusetts General Hospital, Boston. · Department of Medicine, Cardio-Oncology Program, Vanderbilt School of Medicine, Nashville, Tennessee. · Pubmed 26539793
2015
  • Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA · Pubmed 26443566
  • From the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston (H.J.B.); and Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (M.M.). · Pubmed 26200984
  • International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland. Electronic address: · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA. · International Breast Cancer Study Group Coordinating Center, Bern, Switzerland. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Dana-Farber Cancer Institute and Alliance for Clinical Trials in Oncology, Boston, MA, USA. · Medical Oncology, Osp Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo, Italy. · Medical Oncology, Ospedale di Circolo and Fondazione Macchi, and International Breast Cancer Study Group, Varese, Italy. · Medical Oncology, Centro di Riferimento Oncologico, and International Breast Cancer Study Group, Aviano, Italy. · Breast Center, Kantonsspital St Gallen, Swiss Group for Clinical Cancer Research (SAKK), and International Breast Cancer Study Group, St Gallen, Switzerland. · Department of Oncology, University Hospital of Udine, University of Udine and International Breast Cancer Study Group, Udine, Italy. · Oncology Unit, Salvatore Maugeri Foundation, and International Breast Cancer Study Group, Pavia, Italy. · Surgical Oncology, Breast Services, Tata Memorial Hospital, and International Breast Cancer Study Group, Mumbai, India. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Institute of Oncology of Southern Switzerland, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, Lugano Viganello, Switzerland. · University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. · Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne and Australia and New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia, and International Breast Cancer Study Group. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · International Breast Cancer Study Group and University of Sydney, Sydney, NSW, Australia. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Frontier Science and Technology Research Foundation, Boston, MA, USA. · Program for Breast Health (Senology), European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland. · Tom Baker Cancer Centre and National Cancer Institute of Canada Clinical Trials Group, Calgary, AB, Canada. · Pubmed 26092816
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. · Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: · Pubmed 26279133
  • Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. · Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: · Pubmed 26211823
  • Dana-Farber Cancer Institute, Boston, MA. Electronic address: · Brigham and Women's Hospital, Boston, MA. · Case Comprehensive Cancer Center, Cleveland, OH. · Mt Kisco Medical Group, Mt Kisco, NY. · Dana-Farber Cancer Institute, Boston, MA. · Massachusetts General Hospital, Boston, MA. · Beth Israel Deaconess Medical Center, Boston, MA. · Pubmed 25205424
2014
  • Stanford University School of Medicine, Stanford, CA · University of Florida Health Cancer Center, Orlando, FL. · MD Anderson Cancer Center, Houston, TX. · Dana-Farber Cancer Institute, Boston, MA. · Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and. · Johns Hopkins Cancer Center, Baltimore, MD. · Pubmed 24888802
  • From the Dana-Farber Cancer Institute, Boston, MA. · Pubmed 24857085
2013
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. · Pubmed 23906475
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: · Pubmed 24074776
  • Dana-Farber Cancer Institute, 450 Brookline Avenue, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. · Pubmed 23915750
2012
  • Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. · Pubmed 22614986
2011
  • Harvard Medical School, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Pubmed 21600381
  • Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 21600379
2010
  • Dana-Farber Cancer Institute, Boston, MA, USA. · Pubmed 20625130
  • Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. · Pubmed 20620932
  • Dana-Farber Cancer Institute, 44 Binney St, Boston, MA, USA. · Pubmed 20142587
2009
  • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, USA. · Pubmed 19675333
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. · Pubmed 19914532
2008
  • Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA. · Pubmed 19209136
2017
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Wisconsin Carbone Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 28404755
  • Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy. · Pubmed 28654365
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
  • Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea · Pubmed 27022111
2015
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 26656517
  • Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Pubmed 25605863
  • From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.). · Pubmed 25564897
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
  • Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO. · Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO. · Pubmed 25348000
  • Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. · Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. · Pubmed 24934787
  • Ines Vaz-Luis, Melissa E. Hughes, Harold J. Burstein, Jane C. Weeks, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital, Boston, MA; Ines Vaz-Luis, Instituto de Medicina Molecular, Lisbon, Portugal; Rebecca A. Ottesen and Rizvan Mamet, City of Hope, Duarte; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; Stephen B. Edge, Roswell Park Cancer Institute, Buffalo, NY; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Ana M. Gonzalez-Angulo and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX. · Ines Vaz-Luis, Melissa E. Hughes, Harold J. Burstein, Jane C. Weeks, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital, Boston, MA; Ines Vaz-Luis, Instituto de Medicina Molecular, Lisbon, Portugal; Rebecca A. Ottesen and Rizvan Mamet, City of Hope, Duarte; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; Stephen B. Edge, Roswell Park Cancer Institute, Buffalo, NY; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Ana M. Gonzalez-Angulo and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24888816
  • From the aDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, and bDepartment of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio. · Pubmed 24453294
2013
  • Affiliation of authors: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA. · Pubmed 24262439
  • Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA, · Pubmed 24062210
  • Department of Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 23645007
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA. · Pubmed 23829891
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Pubmed 23349386
2012
  • Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA. · Pubmed 23001754
  • Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. · Pubmed 23032626
  • Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. · Pubmed 22017599
  • Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. · Pubmed 21720992
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. · Pubmed 21531783
2011
  • Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Pubmed 21482957
  • Department of Surgical Oncology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. · Pubmed 21713372
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. · Pubmed 21376386
  • Dana-Farber Cancer Institute, 44 Binney St (Dana 1230), Boston MA 02115, USA. · Pubmed 21205755
2010
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 20497961
2009
  • Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer 224, Boston, MA 02115, USA. · Pubmed 19294501
  • Center for Outcomes and Policy Research, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Smith 271, Boston, MA 02115, USA. · Pubmed 19652071
  • Department of Cancer Biology/Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. · Pubmed 19404916
2008
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA. · Pubmed 19322949
Probable:    University of Michigan   Contact    
2016
  • Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI. · Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI · Pubmed 26931400
2017
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Wisconsin Carbone Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 28404755
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
2015
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 26656517
  • Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Pubmed 25605863
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
Probable:    American Society of Clinical Oncology      
2016
  • Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI. · Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI · Pubmed 26931400
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
2015
  • Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Pubmed 25605863
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 101 total) written by Dr. Harold Burstein about Breast Neoplasms:

  • NCCN Guidelines Insights: Breast Cancer, Version 1.2017. 2017
  • Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? 2017
  • Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. 2017
  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. 2017
  • Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. 2017
  • Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. 2016
  • Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. 2016
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. 2016
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. 2016
  • Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? 2016
Show List of Full Article Records
Google Searches

Learn more about Dr. Harold Burstein using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Harvard University
University of Michigan
American Society of Clinical Oncology
Affiliation Timeline What is this?
Harvard University
2017
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts. · Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts2Associate Editor, JAMA. · Pubmed 27918782
  • Seth A. Wander, Erica L. Mayer, and Harold J. Burstein, Dana-Farber Cancer Institute; Brigham & Women's Hospital; Harvard Medical School, Boston, MA. · Pubmed 28580881
  • Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy. · Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. · Klinik St. Anna, Luzern, Switzerland. · German Breast Group, Neu-Isenburg, Germany. · Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Medical Oncology, Institut Jules Bordet, UniversitÕ Libre de Bruxelles, Brussels, Belgium. · Tumor and Breast Center ZeTuP, St. Gallen. · Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland. · Institut de Cancérologie Gustave Roussy, Villejuif, France. · Memorial Sloan Kettering Cancer Center, New York, USA. · Karolinska Institute and University Hospital, Stockholm, Sweden. · University of Bordeaux, Bordeaux, France. · Universitäts-Frauenklinik Tübingen, Tübingen, Germany. · Champalimaud Cancer Centre, Lisbon, Portugal. · Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. · Institut für Pathologie, Charité Universitätsmedizin Berlin, Berlin, Germany. · Azienda Usl Toscana Centro, Prato, Italy. · Rigshospitalet, Copenhagen, Denmark. · Peter McCallum Cancer Centre, Melbourne, Australia. · Marmara University School of Medicine, Istanbul, Turkey. · University of Toronto, Mount Sinai Hospital, Toronto, Canada. · University of Munich, München, Germany. · Comprehensive Cancer Center, University of Michigan, Ann-Arbor, USA. · National Taiwan University Hospital, Taipei, Taiwan. · University of Ulm, Ulm, Germany. · The National Cancer Institute, Cairo University, Cairo, Egypt. · Medical University of Gdansk, Gdansk, Poland. · Hospital Affiliated to Military Medical Science, Beijing, China. · Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrensky University Hospital, Gothenburg, Sweden. · Baylor College of Medicine, Houston, USA. · Institute of Oncology Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland. · Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Canada. · National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea. · Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. · LKH Salzburg, Paracelsus Medical University Clinics, Salzburg, Austria. · N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation. · Fudan University Cancer Hospital, Shanghai, China. · The Royal Marsden, Sutton, Surrey, UK. · Graduate School of Medicine Kyoto University, Sakyo-ku, Kyoto City, Japan. · Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. · University of Milan, Milan. · Istituto Europeo di Oncologia, Milan, Italy. · Hamamatsu Oncology Center, Hamamatsu, Japan. · McMaster University, Hamilton, Canada. · National Cancer Center, Chaoyang District, Beijing, China. · Pubmed 28838210
2016
  • Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI. · Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI · Pubmed 26931400
  • Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Department of Breast Oncology Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. Electronic address: · Department of Surgery, McGill Hospital, Boston, MA, USA. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · Department of Clinical Medicine and Surgery, University Federico II, Corso Umberto I 40, Naples, Italy. Electronic address: · Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy. Electronic address: · General Surgery, Department of Advanced Biomedical Science, University Federico II, Corso Umberto I 40, Naples, Italy. Electronic address: · Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA. Electronic address: · Pubmed 27825710
  • Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. · Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA. · Program in Women's Oncology, Women and Infants Hospital of Rhode Island and Alpert Medical School of Brown University, Providence, RI, USA. · Department of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · Alliance Statistics and Data Center, M D Anderson Cancer Center, Houston, TX, USA. · Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. · Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA. · Department of Medical Oncology, City of Hope Medical Center, Los Angeles, CA, USA. · Department of Surgery, Mount Sinai School of Medicine, New York, NY, USA. · Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · Pubmed 27704226
  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. · Pubmed 27631400
  • Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. · Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. · Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA. · Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. · Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. · Pubmed 27484879
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison, New York. · Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. · Breast Cancer Research, Sarah Cannon Research Institute, Nashville, Tennessee. · Department of Medicine, Duke University Medical Center, Durham, North Carolina. · Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Chicago, Illinois. · Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco. · Department of Medicine, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis. · Department of Medicine, Washington University School of Medicine, St Louis, Missouri. · Department of Hematology Oncology, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, New York. · Department of Oncology, The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. · Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. · Department of Medicine, Massachusetts General Hospital, Boston. · Department of Medicine, Cardio-Oncology Program, Vanderbilt School of Medicine, Nashville, Tennessee. · Pubmed 26539793
2015
  • Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA · Pubmed 26443566
  • From the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston (H.J.B.); and Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (M.M.). · Pubmed 26200984
  • International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland. Electronic address: · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA. · International Breast Cancer Study Group Coordinating Center, Bern, Switzerland. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Dana-Farber Cancer Institute and Alliance for Clinical Trials in Oncology, Boston, MA, USA. · Medical Oncology, Osp Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo, Italy. · Medical Oncology, Ospedale di Circolo and Fondazione Macchi, and International Breast Cancer Study Group, Varese, Italy. · Medical Oncology, Centro di Riferimento Oncologico, and International Breast Cancer Study Group, Aviano, Italy. · Breast Center, Kantonsspital St Gallen, Swiss Group for Clinical Cancer Research (SAKK), and International Breast Cancer Study Group, St Gallen, Switzerland. · Department of Oncology, University Hospital of Udine, University of Udine and International Breast Cancer Study Group, Udine, Italy. · Oncology Unit, Salvatore Maugeri Foundation, and International Breast Cancer Study Group, Pavia, Italy. · Surgical Oncology, Breast Services, Tata Memorial Hospital, and International Breast Cancer Study Group, Mumbai, India. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Institute of Oncology of Southern Switzerland, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, Lugano Viganello, Switzerland. · University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. · Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne and Australia and New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia, and International Breast Cancer Study Group. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · International Breast Cancer Study Group and University of Sydney, Sydney, NSW, Australia. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Frontier Science and Technology Research Foundation, Boston, MA, USA. · Program for Breast Health (Senology), European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland. · Tom Baker Cancer Centre and National Cancer Institute of Canada Clinical Trials Group, Calgary, AB, Canada. · Pubmed 26092816
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. · Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: · Pubmed 26279133
  • Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. · Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: · Pubmed 26211823
  • Dana-Farber Cancer Institute, Boston, MA. Electronic address: · Brigham and Women's Hospital, Boston, MA. · Case Comprehensive Cancer Center, Cleveland, OH. · Mt Kisco Medical Group, Mt Kisco, NY. · Dana-Farber Cancer Institute, Boston, MA. · Massachusetts General Hospital, Boston, MA. · Beth Israel Deaconess Medical Center, Boston, MA. · Pubmed 25205424
2014
  • Stanford University School of Medicine, Stanford, CA · University of Florida Health Cancer Center, Orlando, FL. · MD Anderson Cancer Center, Houston, TX. · Dana-Farber Cancer Institute, Boston, MA. · Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and. · Johns Hopkins Cancer Center, Baltimore, MD. · Pubmed 24888802
  • From the Dana-Farber Cancer Institute, Boston, MA. · Pubmed 24857085
2013
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. · Pubmed 23906475
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: · Pubmed 24074776
  • Dana-Farber Cancer Institute, 450 Brookline Avenue, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. · Pubmed 23915750
2012
  • Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. · Pubmed 22614986
2011
  • Harvard Medical School, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Pubmed 21600381
  • Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 21600379
2010
  • Dana-Farber Cancer Institute, Boston, MA, USA. · Pubmed 20625130
  • Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. · Pubmed 20620932
  • Dana-Farber Cancer Institute, 44 Binney St, Boston, MA, USA. · Pubmed 20142587
2009
  • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, USA. · Pubmed 19675333
  • Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. · Pubmed 19914532
2008
  • Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA. · Pubmed 19209136
2017
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Wisconsin Carbone Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 28404755
  • Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy. · Pubmed 28654365
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
  • Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea · Pubmed 27022111
2015
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 26656517
  • Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Pubmed 25605863
  • From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.). · Pubmed 25564897
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
  • Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO. · Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO. · Pubmed 25348000
  • Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. · Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. · Pubmed 24934787
  • Ines Vaz-Luis, Melissa E. Hughes, Harold J. Burstein, Jane C. Weeks, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital, Boston, MA; Ines Vaz-Luis, Instituto de Medicina Molecular, Lisbon, Portugal; Rebecca A. Ottesen and Rizvan Mamet, City of Hope, Duarte; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; Stephen B. Edge, Roswell Park Cancer Institute, Buffalo, NY; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Ana M. Gonzalez-Angulo and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX. · Ines Vaz-Luis, Melissa E. Hughes, Harold J. Burstein, Jane C. Weeks, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital, Boston, MA; Ines Vaz-Luis, Instituto de Medicina Molecular, Lisbon, Portugal; Rebecca A. Ottesen and Rizvan Mamet, City of Hope, Duarte; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; Stephen B. Edge, Roswell Park Cancer Institute, Buffalo, NY; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Ana M. Gonzalez-Angulo and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24888816
  • From the aDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, and bDepartment of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio. · Pubmed 24453294
2013
  • Affiliation of authors: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA. · Pubmed 24262439
  • Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA, · Pubmed 24062210
  • Department of Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 23645007
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA. · Pubmed 23829891
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Pubmed 23349386
2012
  • Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA. · Pubmed 23001754
  • Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. · Pubmed 23032626
  • Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. · Pubmed 22017599
  • Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. · Pubmed 21720992
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. · Pubmed 21531783
2011
  • Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Pubmed 21482957
  • Department of Surgical Oncology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. · Pubmed 21713372
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. · Pubmed 21376386
  • Dana-Farber Cancer Institute, 44 Binney St (Dana 1230), Boston MA 02115, USA. · Pubmed 21205755
2010
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 20497961
2009
  • Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer 224, Boston, MA 02115, USA. · Pubmed 19294501
  • Center for Outcomes and Policy Research, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Smith 271, Boston, MA 02115, USA. · Pubmed 19652071
  • Department of Cancer Biology/Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. · Pubmed 19404916
2008
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA. · Pubmed 19322949
University of Michigan
2016
  • Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI. · Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI · Pubmed 26931400
2017
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Wisconsin Carbone Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 28404755
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
2015
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 26656517
  • Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Pubmed 25605863
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
American Society of Clinical Oncology
2016
  • Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI. · Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI · Pubmed 26931400
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
2015
  • Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL. · Pubmed 25605863
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
Memorial Sloan-Kettering Cancer Center
2015
  • From the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston (H.J.B.); and Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (M.M.). · Pubmed 26200984
2017
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Wisconsin Carbone Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 28404755
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
  • Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 26884586
2015
  • From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network. · Pubmed 26656517
  • From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.). · Pubmed 25564897
2014
  • Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. · Pubmed 24868023
  • Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX. · Pubmed 24663048
  • Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO. · Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO. · Pubmed 25348000
  • Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. · Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. · Pubmed 24934787
Cornell University
2015
  • From the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston (H.J.B.); and Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (M.M.). · Pubmed 26200984
2016
  • Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. · Pubmed 27217461
2015
  • From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.). · Pubmed 25564897
Miscellaneous institutions in Boston
2011
  • Dana-Farher Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA. · Pubmed 22015280
84 Other Locations Show
Yearly article counts 0510121111151371520